Q-omics provides the consensus-scored TREHP1 profile across patient tissues and cancer cell-line models. TREHP1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TREHP1 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, TREHP1 RNA expression shows 6,318 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, LUAD, and STAD as cancer lineages where TREHP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TREHP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TREHP1 survival associations across molecular data types. TREHP1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TREHP1 RNA expression–survival associations across cancer types. High TREHP1 expression shows unfavorable associations in THCA, but favorable associations in MESO, LUAD, BLCA, CESC and SARC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for TREHP1 RNA expression.
This table summarizes TREHP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TREHP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TREHP1 shows lower tumor expression in LUAD, LUSC, KIRC, THCA, READ and BRCA. The LUAD box plot shows higher TREHP1 RNA expression in normal versus tumor tissue (log2 FC = −1.184, t-test p < 0.001).
This table shows molecular features associated with TREHP1 in patient tissues and cancer cell lines. In patient samples, TREHP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
